文献速递妇科

多囊卵巢综合征与卵巢肿瘤风险

Polycystic ovary syndrome and the risk of ovarian tumours.
PubMed 文献 · Gynecol Oncol · 2025-07-12

这项回顾性队列研究随访25年,纳入479759名参与者,其中80131例多囊卵巢综合征(PCOS)患者与399628名匹配对照(1:5)。调整肥胖、出生国家和教育后,PCOS患者上皮性卵巢癌风险未升高(aHR 1.00,95%CI 0.64-1.55),但交界性卵巢肿瘤(aHR 1.61,95%CI 1.16-2.23)和非上皮性卵巢癌(aHR 4.26,95%CI 2.50-7.03)风险更高;作者认为这些发现不支持对PCOS女性进行筛查或改变随访。

要点

  • PCOS患者上皮性卵巢癌风险未升高,aHR 1.00(95%CI 0.64-1.55)。
  • PCOS患者交界性卵巢肿瘤风险升高,aHR 1.61(95%CI 1.16-2.23)。
  • PCOS患者非上皮性卵巢癌风险升高,aHR 4.26(95%CI 2.50-7.03),其中间质瘤风险增加七倍。

核心结论

  • PCOS女性发生非上皮性卵巢癌和交界性卵巢肿瘤的风险高于无PCOS女性。
  • 尽管风险估计值较高,但非上皮性卵巢癌是一种罕见诊断。
  • 该研究结果可能为PCOS与卵巢癌(主要为非上皮性卵巢癌)的潜在机制提供见解,但不表明有必要对PCOS女性进行筛查或改变随访。

研究设计与样本

  • 回顾性队列研究,随访25年。
  • 纳入479759名参与者,其中80131例诊断为PCOS,399628名为匹配对照(1:5比例)。
  • 数据来自瑞典登记系统,主要为全国患者登记册和瑞典全国癌症登记册。
  • 使用Cox回归计算粗风险比和调整风险比及95%置信区间(95%CI)。

主要发现

  • 研究期间共450人被诊断为卵巢癌或卵巢交界性肿瘤(BOT)。
  • 调整肥胖、出生国家和教育后,PCOS女性上皮性卵巢癌(EOC)风险未升高,aHR 1.00(95%CI 0.64-1.55)。
  • PCOS女性交界性卵巢肿瘤风险更高,aHR 1.61(95%CI 1.16-2.23)。
  • PCOS女性非上皮性卵巢癌风险更高,aHR 4.26(95%CI 2.50-7.03)。
  • 进一步亚组分析非上皮性卵巢癌时,间质瘤在PCOS女性中风险增加七倍。

临床怎么用

  • 作者认为,该研究结果不表明有必要对PCOS女性进行筛查或改变随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the risk of ovarian cancer (OC) and its subtypes among women with PCOS. METHODS: This is a retrospective cohort study with a follow-up of 25 years. The study included 479,759 participants, of which 80,131 were diagnosed with PCOS and 399,628 were matched controls (1:5 ratio). The data were obtained from Swedish registers, primarily the National Patient Registry and the Swedish National Cancer Registry. We used Cox regression to calculate hazard ratios, both crude and adjusted, and 95 % confidence intervals (95 % CI). RESULTS: During the study period, 450 individuals were diagnosed with OC or borderline tumour of the ovary (BOT). Following adjustment for obesity, country of birth and education, women with PCOS did not have an increased risk of epithelial ovarian cancer (EOC), aHR: 1.00 (95 % CI 0.64-1.55). However, the risks of developing BOT and non-EOC were higher in women with PCOS, aHR: 1.61 (95 % CI 1.16-2.23) and aHR: 4.26 (95 % CI 2.50-7.03), respectively. When further subgrouping non-EOC, stromal tumours stood out with a seventh-fold increased risk among women with PCOS. CONCLUSION: Women with PCOS are at higher risk of developing non-EOC and BOT than women without PCOS. Although the risk estimate is high, non-EOC is a rare diagnosis. Thus, the findings of this study may provide insights into the underlying mechanisms of PCOS and ovarian cancer, primarily non-EOC. However, they do not indicate any necessity for screening or alterations in the follow-up of women with PCOS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hübinette M, Sundström-Poromaa I, Persson S, et al. Polycystic ovary syndrome and the risk of ovarian tumours. Gynecol Oncol. 2025. PMID: 40652611. doi:10.1016/j.ygyno.2025.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。